You are here

ANTIIDIOTYPE MAB:AN ANTIANGIOGENIC /ANTIMETASTATIC AGENT

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA096368-01
Agency Tracking Number: CA096368
Amount: $122,433.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
PIVOTAL BIOSCIENCES 8721 SANTA MONICA BLVD, STE 100
LOS ANGELES, CA 90069
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 FRANCIS MARKLAND
 (323) 224-7981
 MARKLAND@HSC.USC.EDU
Business Contact
 DIMITRI VILLAR
Phone: (310) 229-4545
Email: DVILLARD@LOOP.COM
Research Institution
 UNIVERSITY OF SOUTHERN CALIFORNIA
 
USC
LOS ANGELES, CA 90089
United States

 Nonprofit College or University
Abstract

Angiogenesis (new blood vessel formation) is a critical step for tumor growth and metastasis, and its inhibition is currently the most promising approach for cancer therapy. Contortrostatin (ON) is a protein isolated from southern copperhead snake venom, which has been
shown to effectively block angiogenesis, as well as metastasis. The potent
inhibitory effect of CN on cancer progression has been proven in animal models
of several types of cancer. However, two problems hinder its clinical
application. First, ON is recognized by the human immune system as a foreign
protein. Therefore, repetitive delivery of ON to patients induces the
production of antibodies that neutralize its activity. Second, ON is eliminated
from the circulation too quickly to exert a sustained effect. We propose to
circumvent these obstacles by making an antibody to the ON antibody
(antiidiotype) that will mimic the anti-cancer activity of native ON. This ON
surrogate can then be genetically modified to resemble a human antibody
(humanized), which will evade rejection by the immune system. The life span of
this 'humanized" antibody in circulation will be similar to native
immunoglobulin and thus ideal for long-term therapy. This project should result
in a biopharmaceutical lead for antiangiogenic therapy.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government